BRISBANE, Calif., March 16, 2026 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical corporate advancing the following technology platform of centered immunotherapies aimed toward neuroinflammatory sicknesses that affect just about 10 million other folks international, nowadays introduced that it has granted inducement to a brand new non-executive worker below the phrases of the 2022 Employment Inducement Award Plan. The fairness award was once licensed on March 12, 2026, in response to Nasdaq Record Rule 5635(c)(4).
The brand new non-executive worker won an choice to buy 20,000 stocks of Annexon commonplace inventory. The choice carries a ten-year time period and an workout value in line with proportion equivalent to $5.66, which was once the final value of Annexon’s commonplace inventory on March 13, 2026, the date of grant, and vests over 4 years, with 25% of the stocks underlying the choices vesting at the first anniversary of the grant date and an extra 1/forty eighth of the stocks vesting per month thereafter, topic to persisted provider throughout the acceptable vesting dates.
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is advancing the following technology platform of centered immunotherapies for just about 10 million other folks international residing with critical neuroinflammatory sicknesses. Our founding medical means specializes in C1q, the beginning molecule of a potent inflammatory pathway that after misdirected can result in tissue injury and lack of serve as in a number of sicknesses. Our centered remedies are designed to prevent classical complement-driven neuroinflammation at its supply to offer significant useful receive advantages and change the process illness. Annexon’s project is to ship game-changing remedies to sufferers in order that they are able to are living their very best lives. To be told extra discuss with annexonbio.com.
Investor Touch:
